StockData
RNANasdaqPharmaceutical PreparationsFiscal year ends December 31

Atrium Therapeutics, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$7.61−0.06 (-0.78%)

Close on Oct 19, 2026

Market cap
$130.18M
P/E (TTM)
–
Dividend yield
–

SEC filings

8 of Atrium Therapeutics's most recent filings on SEC EDGAR

DocumentFormPeriodFiledSource
Current report8-KOct 7, 2026Oct 8, 2026SEC EDGAR
Quarterly report10-QJun 30, 2026Aug 13, 2026SEC EDGAR
Current report8-KAug 13, 2026Aug 13, 2026SEC EDGAR
Current report8-KJul 14, 2026Jul 14, 2026SEC EDGAR
Quarterly report10-QMar 31, 2026May 14, 2026SEC EDGAR
Current report8-KMay 14, 2026May 14, 2026SEC EDGAR
Current report8-KFeb 26, 2026Feb 27, 2026SEC EDGAR
Current report8-KFeb 26, 2026Feb 26, 2026SEC EDGAR